Trovagene’s PCM-075 Increases Zytiga’s Punch Against Prostate Cancer, Studies Show
News
Trovagene’s enzyme inhibitor PCM-075 increases the punch of the prostate cancer therapy Zytiga (abiraterone), preclinical-trial studies show. PCM-075 is a selective polo-like kinase 1 (PLK1) inhibitor. It inhibits a protein called PLK1, whose levels ... Read more